Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Sell
23
BDUUY Quote, Financials, Valuation and Earnings
Last price:
$32.33
Seasonality move
:
-0.85%
Day range:
$32.33 - $32.33
52-week range:
$31.21 - $32.49
Dividend yield:
2.78%
P/E ratio:
28.07x
P/S ratio:
4.20x
P/B ratio:
4.39x
Volume:
--
Avg. volume:
--
1-year change:
-0.49%
Market cap:
$12.8B
Revenue:
$3.1B
EPS (TTM):
$1.15
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Bangkok Dusit Medical Services PCL has -- downside to fair value with a price target of -- per share.
BDUUY vs. S&P 500
-
Over the past 5 trading days, Bangkok Dusit Medical Services PCL has overperformed the S&P 500 by 1.07% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bangkok Dusit Medical Services PCL does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bangkok Dusit Medical Services PCL has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Bangkok Dusit Medical Services PCL reported revenues of $805.5M.
Earnings Growth
-
Bangkok Dusit Medical Services PCL has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Bangkok Dusit Medical Services PCL reported earnings per share of $0.32.
Enterprise value:
13B
EV / Invested capital:
--
Price / LTM sales:
4.20x
EV / EBIT:
22.04x
EV / Revenue:
4.25x
PEG ratio (5yr expected):
2.39x
EV / Free cash flow:
40.69x
Price / Operating cash flow:
40.17x
Enterprise value / EBITDA:
17.02x
Gross Profit (TTM):
$1.1B
Return On Assets:
10.85%
Net Income Margin (TTM):
14.85%
Return On Equity:
15.75%
Return On Invested Capital:
14.33%
Operating Margin:
19.39%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2.6B | $2.9B | $3.1B | $736.3M | $805.5M | |
| Gross Profit | $959.3M | $1.1B | $1.1B | $278.3M | $304.7M | |
| Operating Income | $485.5M | $541.6M | $581.4M | $143.8M | $156.2M | |
| EBITDA | $659.2M | $718.2M | $764.3M | $188.4M | $205.5M | |
| Diluted EPS | $0.90 | $1.03 | $1.15 | $0.28 | $0.32 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1B | $731.5M | $803.7M | $645.3M | $692.1M | |
| Total Assets | $4.5B | $3.9B | $4.1B | $3.9B | $4.4B | |
| Current Liabilities | $374.8M | $475.5M | $596M | $505.2M | $644M | |
| Total Liabilities | $1.5B | $1.2B | $1.4B | $1.2B | $1.4B | |
| Total Equity | $3.1B | $2.6B | $2.7B | $2.7B | $3B | |
| Total Debt | $694.3M | $469.8M | $463.4M | $287.7M | $307.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $579.2M | $597.6M | $651M | $120.8M | $113.9M | |
| Cash From Investing | -$168.7M | -$222.4M | -$322.8M | -$66.6M | -$121.6M | |
| Cash From Financing | -$361M | -$513.4M | -$339.4M | -$66.2M | -$41.3M | |
| Free Cash Flow | $434.3M | $359.3M | $319.8M | $54.2M | $11.1M | |
BDUUY
Sector
Market Cap
$12.8B
--
Price % of 52-Week High
99.51%
--
Dividend Yield
2.78%
--
Shareholder Yield
--
--
1-Year Price Total Return
-0.49%
--
Beta (5-Year)
--
--
Dividend yield:
2.78%
Annualized payout:
$0.81
Payout ratio:
69.36%
Growth streak:
2 years
Technicals
8-day SMA
Sell
Level
$32.33
200-day SMA
Buy
Level
$32.26
Bollinger Bands (100)
Sell
Level
32.33 - 32.33
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$32.33
Relative Strength Index (RSI14)
Buy
Level
94.33
ADX Line
Neutral
Level
89.09
Williams %R
Buy
Level
0
50-day SMA
Sell
Level
$32.33
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
200
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.1977)
Buy
CA Score
(Annual)
Level (1.1989)
Buy
Beneish M-Score
(Annual)
Level (-2.5524)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-2.2973)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bangkok Dusit Medical Services PCL operates a network of hospitals throughout Thailand under the Bangkok Hospital, Phyathai Hospital, Samitivej Hospital, Paolo Hospital, BNH Hospital, and Royal International Hospital brands. The company has two business segments namely, hospital operations and other businesses that support hospital business such as medical laboratories, production and distribution of pharmaceutical products/medical equipment/saline, pharmacies, assets management for healthcare business, accounting services, technology and information services, training business and insurance broker. The company's hospital operations generate the vast majority of its revenue.
Stock Forecast FAQ
In the current month, BDUUY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BDUUY average analyst price target in the past 3 months is --.
-
Where Will Bangkok Dusit Medical Services PCL Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bangkok Dusit Medical Services PCL share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Bangkok Dusit Medical Services PCL?
Analysts are divided on their view about Bangkok Dusit Medical Services PCL share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bangkok Dusit Medical Services PCL is a Sell and believe this share price will rise from its current level to --.
-
What Is Bangkok Dusit Medical Services PCL's Price Target?
The price target for Bangkok Dusit Medical Services PCL over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BDUUY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bangkok Dusit Medical Services PCL is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BDUUY?
You can purchase shares of Bangkok Dusit Medical Services PCL via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bangkok Dusit Medical Services PCL shares.
-
What Is The Bangkok Dusit Medical Services PCL Share Price Today?
Bangkok Dusit Medical Services PCL was last trading at $32.33 per share. This represents the most recent stock quote for Bangkok Dusit Medical Services PCL. Yesterday, Bangkok Dusit Medical Services PCL closed at $32.33 per share.
-
How To Buy Bangkok Dusit Medical Services PCL Stock Online?
In order to purchase Bangkok Dusit Medical Services PCL stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
